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 1 
Abstract 2 
Objectives: Vancomycin is currently the primary option treatment for 3 
methicillin-resistant Staphylococcus aureus (MRSA). However, an increasing 4 
number of MRSA isolates with high minimum inhibitory concentrations (MICs), 5 
within the susceptible range (vancomycin MIC creep), are being reported 6 
worldwide.  7 
Resorting to a meta-analysis approach, this study aims to assess the 8 
evidence of vancomycin MIC creep.  9 
Methods: We searched for studies in the Pubmed database. The inclusion 10 
criteria for study eligibility included the possibility of retrieving from the 11 
reported data values of vancomycin MIC and information concerning the 12 
applied MIC methodology.  13 
Results: The mean values of vancomycin MICs, of all 29.234 S. aureus 14 
isolates reported in the 55 studies included in the meta-analysis, were 1.23 15 
mg/L (CI (95%) 1.13 – 1.33) and 1.20 mg/L (CI (95%) 1.13 – 1.28) determined 16 
by Etest and BMD method, respectively. No significant differences were 17 
observed between these two methodologies. We found negative correlation 18 
between pooled mean/pooled proportion and time strata.  19 
Conclusions: We have found no evidence of the MIC creep phenomenon.  20 
 21 
 22 
Key words 23 
Staphylococcus aureus; vancomycin; MIC creep, meta-analysis, MIC 24 
methodologies 25 
 26 
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 1 
1. Introduction 2 
 3 
Nowadays, Staphylococcus aureus (S. aureus) is one of the most common 4 
pathogen causing severe infections (1). Infections caused by methicillin-5 
resistant Staphylococcus aureus (MRSA) are associated with increased 6 
morbidity, longer antibiotic therapy, higher healthcare costs, prolonged 7 
hospitalization and increased risk of death (2). 8 
The first option for the treatment of invasive MRSA infections is the 9 
glycopeptide vancomycin, which continues to be the gold standard approach 10 
in this context (3). The utilization of vancomycin has been increasing 11 
continuously since mid 1980’s, resulting in the emergence of MRSA with 12 
reduced susceptibility to vancomycin (2). Recently, a phenomenon of gradual 13 
increase in the value of glycopeptides MIC (Minimal Inhibitory Concentration) 14 
for S. aureus was observed and reported in the literature as MIC creep (4). 15 
The publications related to MIC creep included studies that report increase in 16 
the mean vancomycin MIC as well as studies that did not confirm these 17 
findings in MSRA (3, 5, 6). In this context, and as a result of the reported 18 
vancomycin therapy failure in patients with S. aureus infections with a MIC ≥ 4 19 
mg/L, the Clinical and Laboratory Standards Institute (CLSI) reduced 20 
vancomycin breakpoints from ≤ 4mg/L to ≤ 2mg/L, for susceptible S. aureus, 21 
and from ≥ 32 mg/L to ≥ 16mg/L for resistant S. aureus. These changes 22 
aimed to increase the sensitivity of the detection of non-susceptible isolates 23 
(3, 7). The apparent increase in vancomycin MIC amongst MRSA, observed 24 
in recent years, can represent the first step towards the appearance of fully 25 
resistant isolates. Patients with MRSA isolates that exhibit MIC creep might 26 
experience poorer clinical outcomes, including delayed treatment response, 27 
increased mortality, increased rate of relapse, extended hospitalization or 28 
overall increased cost of hospitalization (2, 7, 8).  29 
Soriano, et al. showed that mortality associated with MRSA bacteremia was 30 
significantly higher when the empirical antibiotic was inappropriate and when 31 
vancomycin was empirically used for treatment of infection with strains with 32 
high vancomycin MIC (>1 mg/L) (9). 33 
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The MIC creep phenomenon may be influenced by the type of microbiological 1 
susceptibility test used (Etest, broth microdilution (BMD) or automated 2 
system) (2, 10), type of S. aureus strain or type of patient population 3 
evaluated (2). The gold standard for measuring MIC remains BMD (11). 4 
In the literature it is possible to find studies that show vancomycin MIC creep 5 
by using BMD (12) and Etest methods (13), and studies that found no 6 
vancomycin MIC creep when using the same methods (12-14). This 7 
demonstrate inconsistent information about MIC creep phenomenon and 8 
conflicting results have been noted in cases in which MIC creep could not be 9 
detected. Thus, in an attempt to clarify these inconsistencies and conflicting 10 
results, this study aims to assess the evidence of MIC creep, using a meta-11 
analysis, highlighting the type of applied MIC methodologies. 12 
13 
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2. Methods 1 
 2 
2.1. Search Strategy and Selection Criteria  3 
The studies to be included in the meta-analysis approach were retrieved from 4 
Pubmed database. Search query was “methicillin-resistant staphylococcus 5 
aureus” OR "Methicillin-Resistant Staphylococcus aureus"[Mesh]”” OR 6 
“MRSA” AND “vancomycin” OR "vancomycin"[Mesh]”” AND “minimal 7 
inhibitory concentration” OR “MIC” OR “MIC creep” OR “reduced vancomycin 8 
susceptibility” OR “vancomycin susceptibility trends”.  9 
The abstracts of the collected articles were reviewed and a study was 10 
considerable to be eligible for inclusion if included values of vancomycin MIC 11 
and details of the applied MIC methodologies. Selected MIC methodologies 12 
were: microdilution (BMD), Etest, agar diffusion and automated systems. 13 
 14 
2.2. Data Analysis 15 
2.2.1. Data Extraction 16 
After the analysis of both titles and abstracts, the selected studies were 17 
independently assessed and analyzed by three authors (R. Diaz, V. Afreixo 18 
and C. Rodrigues).  19 
Data extracted from the identified studies included MIC vancomycin 20 
information applied methodology, number of studied isolates, source of 21 
isolate, year of study completion and country (supplementary material).  22 
 23 
2.2.2. Data Uniformization 24 
In the cases of the studies that only reported median, minimum (min) and 25 
maximum (max) values, it was assumed the symmetry and mean values were 26 
estimated from the median. To estimate the standard deviation (std), the 27 
authors assumed the uniform with a variable distribution and the std=(max-28 
min)/√12. In order to complete the table of statistics (mean, std, min), all MIC 29 
values ≤0.5 were converted to 0.5. 30 
In studies in which the results were grouped by periods of two years or more, 31 
the count were divided in a uniform manner by periods under review. 32 
To create groups with similar numbers of effects, the following stratification of 33 
study years under analysis was selected, resulting in seven time strata: 34 
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<2000; 2000-2001; 2002-2003; 2004-2005; 2006-2007; 2008-2009 and 1 
≥2010. The time strata <2000 and ≥2010 are created to reach a more uniform 2 
number of studies in each stratum. To aggregate results from different years, 3 
from the same study, weighted averages, combined variances and/or 4 
accumulated frequencies were used. 5 
Some criteria were defined before starting the meta-analysis on the 53 6 
included studies: 1) in studies that presented data of frozen isolates and data 7 
of “at time” isolates, data of “frozen isolates” was used because most of the 8 
studies determined MICs in “frozen isolates” (6); 2) in the case of studies with 9 
data of automated methods, only data of VITEK method was considered since 10 
it is the only common to all studies (15); 3) studies of the same author and 11 
year were identified with A and B (15-18); 4) studies which included different 12 
cities were identified with A and B (3); 5) data presented in more than one 13 
study of the same author were excluded (17, 18). 14 
 15 
2.2.3. Statistical analysis 16 
Homogeneity among studies was computed using the Cochran’s Q statistic 17 
and the I2 statistic. A significant Q statistic suggests that the distribution of 18 
effect sizes around the mean is greater than it would be predicted from 19 
sampling error alone. On the other hand, I2 provides an estimate of the 20 
proportion of the variance in the aggregate effect size that is attributable to 21 
studies heterogeneity, with values of 0.25, 0.50, and 0.75 indicating low, 22 
moderate, and high degrees of heterogeneity.  23 
In order to perform a secondary study, a subgroup analysis was carried out 24 
with the mean of vancomycin MIC and the proportion of S. aureus isolates 25 
with vancomycin MIC ≥ 2 mg/L in four subgroups of regions: (i) Europe, (ii) 26 
USA, (iii) Asia and (iv) others. Due to the significant heterogeneity between 27 
the studies, the pooled prevalence for each group was estimated using the 28 
random-effects model.  29 
To compare the pooled effect size in different groups (subgroups) the Z-test 30 
was used and for simultaneous statistical tests the Sidak correction was 31 
applied (19).  32 
MetaXL 1.0, a tool for meta-analysis in Microsoft Excel, was used to pool 33 
individual prevalence from each study. 34 
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 1 
3. Results 2 
Literature search, based on the keywords described in methods, identified 3 
980 studies (figure 1). After title and abstract analysis, 880 were excluded and 4 
100 full-text articles were reviewed, (1, 3-6, 8, 9, 11-18, 20-104). Of these, 55 5 
studies were included in the meta-analysis (table 1 in online - only appendix), 6 
45 were excluded for the following reasons: data was included in other study 7 
of the same author (2 studies) (87), no MIC data was available (35 studies) 8 
(21, 26, 27, 30, 31, 33, 35, 37, 38, 41, 44, 47, 48, 53, 54, 59, 64, 69, 70, 78, 9 
80, 82, 83, 89, 90, 92, 94, 95, 97, 101, 102, 104), full-text versions unavailable 10 
(2 studies) (75, 77), different guidelines used (2 studies) (47, 103) and meta-11 
analysis and review articles (4 studies) (8, 46, 57, 93).  12 
 13 
 14 
 15 
 16 
 17 
 18 
 19 
 20 
 21 
 22 
 23 
 24 
 25 
 26 
 27 
 28 
 29 
880 studies were excluded.  
Out of inclusion criteria 
980 studies retrieved from literature 
search strategy 
100 studies were reviewed 
55 studies were included in meta-analysis 
45 studies were excluded:  
Data included in other study of the same author (2 studies) 
No MIC data was available (35 studies) 
No full text version available (2 studies)  
Different guidelines used (2 studies) 
Meta-analysis and review articles (4 studies)  
 
Figure 1: Results of literature search.  
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Considering all studies included in the pool (n=55), the mean vancomycin MIC 1 
was 1.20 mg/L (CI (95%) 1.13 – 1.28), 1.23 mg/L (CI (95%) 1.13 – 1.33) and 2 
1.19 mg/L (CI (95%) 1.07 – 1.30), when determined by the BMD method, 3 
Etest method and by the agar method, respectively. The pooled mean of 4 
vancomycin MIC determined resorting to the automated method was lower 5 
comparing with values obtained with the other methods (1.10 mg/L) (table II). 6 
The differences between studied MIC methodologies were not statistically 7 
significant (p values > 0.05, Z-test with Sidak correction for multiple 8 
comparisons). 9 
To evaluate the robustness of our uniformization, sensitivity analysis was 10 
conducted. In four studies the mean value was inferred through the median 11 
(Zhuo2013 (40), Kehrmann2011 (3), Cojutti2015 (24), Patel2009 (79)), 12 
excluding this studies the overall results do not present significant differences, 13 
the overall results are similar with negative correlation values, -0.68 and -0.64 14 
for Etest and BMD, respectively. 15 
 16 
 17 
Table II: Statistical results of pooled mean vancomycin MICs determined resorting to different 18 
MIC testing methodologies. 19 
(1)
 Spearman correlation: correlation between time strata and pooled mean. 20 
 21 
 22 
Considering the pooled mean of vancomycin MIC over each time strata 23 
represented in figure 2 and 3, studies before the year 2000 showed the 24 
highest vancomycin MICs pooled values. After the year 2007 vancomycin MIC 25 
showed a slight decreased (negative Spearman correlation between time 26 
 
MIC testing 
methodologies 
Pooled 
mean 
Confidence Interval 
(95%) Spearman 
correlation (1) 
I^2 
Number of 
independent 
studies 
Number of 
samples Lower 
bound 
Upper 
bound 
MRSA 
BMD 1.20 1.13 1.28 -0.82 98.69 16 8328 
Etest 1.23 1.13 1.33 -0.57 99.61 27 7426 
Agar 1.19 1.07 1.30 - 97.64 6 1626 
Automated 
system 
1.10 0.83 1.38 - 99.24 7 1555 
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strata and pooled mean) (table II). In general, the results were similar with 1 
BMD (figure 2) and Etest (figure 3) methods.  2 
 3 
 4 
Figure 2: Pooled mean of vancomycin MIC determined by the BMD method over time. The bubble 5 
size represents the meta-analysis sub-group weight. 6 
 7 
 8 
 9 
Figure 3: Pooled mean vancomycin MIC determined by the Etest method over time. The bubble 10 
size represents the meta-analysis sub-group weight. 11 
 12 
 13 
Clinical and Laboratory Standards Institute (CLSI) guidelines consider that S. 14 
aureus is susceptible to vancomycin for MICs lower then 2 mg/L (105). 15 
Considering this guideline, the pooled proportion of MRSA isolates with 16 
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vancomycin MIC ≥ 2 mg/L was evaluated and showed to be low, between 1 
14% and 18%, for all the applied testing methods (table III).  2 
 3 
 4 
Table III: Pooled proportion the S. aureus isolates with vancomycin MIC ≥ 2 mg/L determined 5 
resorting to different MIC testing methodologies. 6 
 
MIC testing 
methodologies 
Pooled 
proportion 
Confidence 
Interval (95%) Spearman 
correlation (1) 
I^2 
Number of 
independent 
studies 
Number of 
samples Lower 
bound 
Upper 
bound 
MRSA 
BMD 0.18 0.12 0.25 -0.89 98.48 17 10350 
Etest 0.14 0.10 0.19 -0.64 96.86 27 7389 
Agar 0.15 0.04 0.30 - 98.32 7 2016 
Automated 
system 
0.18 0.05 0.36 - 97.99 6 1406 
(1)
 Spearman correlation: correlation between time strata and pooled proportion. 7 
 8 
 9 
The analysis of the distribution of MRSA isolates with vancomycin MIC ≥ 2 10 
mg/L showed a decrease over time, either with BMD (figure 4) or Etest (figure 11 
5) methods. For the Etest method, a slight oscillation was observed between 12 
2000 and 2007, followed by a tendency to decrease after 2007 (negative 13 
Spearman correlation) (table III).  14 
 15 
 16 
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 1 
Figure 4: Pooled proportion of MRSA isolates with vancomycin MIC ≥ 2 mg/L determined with the 2 
BMD method. The bubble size represents the meta-analysis sub-group weight. 3 
 4 
 5 
 6 
  7 
 8 
Figure 5: Pooled proportion of MRSA isolates with vancomycin MIC ≥ 2 mg/L determined with the 9 
Etest method. The bubble size represents the meta-analysis sub-group weight. 10 
 11 
 12 
Regarding the analysis of the pooled mean of vancomycin MIC by region, 13 
(Europe, USA, Asia and other countries), in Europe the pooled mean of 14 
vancomycin MIC determined with the BMD method was 1.12 mg/L (figure 6 15 
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online-only appendix) and with the Etest method was 1.13 mg/L (figure 7 1 
online-only appendix). In Asia, the pooled mean of vancomycin determined 2 
with the BMD method was 1.17 mg/L (figure 6 online-only appendix) and with 3 
the Etest method was 0.98 mg/L (figure 7 online-only appendix). Regarding 4 
the USA, these values were slightly increased, with values of 1.37mg/L and 5 
1.53 mg/L for the BMD method (figure 6 online-only appendix) and Etest 6 
method (figure 7 online-only appendix), respectively.  7 
By region, the proportion of MRSA isolates with vancomycin MIC ≥ 2 mg/L 8 
was 17% in Europe, 26% in USA and 18% in Asia, for BMD method. For Etest 9 
method the proportion of MRSA isolates was 11% in Europe, 27% in USA and 10 
3% in Asia (table IV).  11 
 12 
 13 
Table IV: Pooled proportion the MRSA isolates with vancomycin MIC ≥ 2 mg/L, by region.  14 
MIC testing 
methodologies 
Region Pooled 
Confidence Interval 
(95%) 
I^2 
Number of 
independent 
studies 
Number of 
samples Lower 
bound 
Upper 
bound 
BMD 
Europe 0.17 0.06 0.31 99.58 5 1585 
USA 0.26 0.00 0.71 
 
4 4518 
Asia 0.18 0.00 0.44 
 
4 3235 
Other 0.10 0.00 0.42 
 
2 435 
Etest 
Europe 0.11 0.04 0.20 98.92 10 1730 
USA 0.27 0.11 0.46 
 
11 4578 
Asia 0.03 0.00 0.09 
 
5 987 
Other 0.23 0.00 0.65 
 
2 435 
 15 
 16 
 17 
 18 
 19 
  20 
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4. Discussion  1 
 2 
This study is the first meta-analysis with a worldwide perspective that 3 
evaluates the trends of vancomycin MIC over time, determined by different 4 
MIC methodologies, and no statistically significant evidence of the MIC creep 5 
phenomenon was detected.  6 
The standard for measuring MIC remains BMD; but this is a labour intensive 7 
technique and many laboratories use the Etest method as an alternative. 8 
These two methods were selected for evaluation in more detail in this work. 9 
The results of the pooled mean of vancomycin MICs for all MRSA isolates 10 
reported with BMD and Etest methods were 1.20mg/L and 1.23mg/L, 11 
respectively and no significant differences were observed between these two 12 
methods. The number of strains studied with agar method was very low when 13 
compared with others methodologies, however the pooled mean of 14 
vancomycin MIC for this method (1.19mg/L) was not significantly different 15 
from the others. Based on clinical laboratory practice, as expected, the pooled 16 
mean of vancomycin MIC determined with an automated method (1.10mg/L) 17 
was lower than the ones determined with other methodologies studied. This 18 
result is consistent with the study of Tomczak, et al., that reports differences 19 
between vancomycin MIC assayed with automated method and Etest method 20 
(4).  21 
When considering pooled mean of vancomycin MIC over time, studies 22 
published before the year 2000 exhibited the highest vancomycin MICs and 23 
after 2007 vancomycin MICs showed a slight decrease. Results were similar 24 
for BMD and Etest methods. These findings are consistent with the results 25 
reported previously by other authors that did not found trends in vancomycin 26 
MIC. Some examples are the SENTRY Antimicrobial Surveillance Program 27 
database, where, between 1998 and 2003, 35,458 S. aureus isolates where 28 
studied (106), a multi-center study of nine US medical centers where 1800 29 
MRSA samples where studied, between 1999 and 2006, (107) and a survey 30 
from Spain that, between 2002 and 2006, evaluated 3141 S. aureus isolates 31 
(12). 32 
Considering the upper vancomycin breakpoint for susceptible S. aureus a 33 
subgroup analysis was carried with the proportion of S. aureus isolates with 34 
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vancomycin MIC ≥ 2 mg/L and comparing the two main testing methods under 1 
analysis the MRSA pooled proportion was very low (11% to 27%). 2 
Additionally, over time strata, both BMD and Etest methods showed a 3 
decrease in vancomycin MIC, strengthening the observation of no evidence of 4 
MIC creep, as supported by the Spearman´s correlation coefficient (table III). 5 
The decrease trends observed in both analysis for the last time-strata, can 6 
suggest a positive impact of implementation of more rigorous clinical 7 
strategies for the management of MRSA infection. 8 
This study also enabled the evaluation of the pooled mean of vancomycin 9 
MIC by region (figure 6 and 7 online-only appendix). The results showed a 10 
lower pooled mean of vancomycin MIC in Europe and a slightly higher pooled 11 
mean of vancomycin MIC in USA. It is expected that an increased value of 12 
vancomycin MIC is related to the overall prevalence of MRSA, with higher 13 
value of vancomycin MIC linked to higher MRSA prevalence. When 14 
correlating our results with the overall prevalence of countries included in the 15 
meta-analysis, this can be found in USA and China where the overall 16 
prevalence of MRSA in USA is 55,9% (56) with a pooled mean of vancomycin 17 
1.12mg/L and 1.13mg/L, determined with BMD and Etest, respectively and in 18 
China with an overall prevalence of MRSA of 46.8% (56) and with a pooled 19 
mean of vancomycin 1.17mg/L for BMD and 0,98 for Etest. 20 
One of the problems of combining data from multiple centres, is that it can 21 
obscure trends that may exist within a given institution(s) or country, because 22 
of differences in patient populations and drug usage patterns. One possible 23 
limitation of our study is the inclusion of large multicenter studies, but the 24 
negative values obtained with Spearman´s correlation coefficient even with 25 
inclusion of these studies, substantiate no evidences of vancomycin MIC 26 
creep over time.  27 
The present study did not detect an increase in vancomycin MIC suggesting 28 
that vancomycin continues to be the standard option in treatment of MRSA 29 
infections when MIC is determined with Etest or BMD methods and in 30 
institutions that continuously evaluate their local susceptibility profiles. Future 31 
studies must focus on the analysis of vancomycin MIC creep on a regional 32 
basis, tested at the same locations and using the same methodologies. 33 
  34 
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 1 
Supplementary material  2 
It includes an Excel file with two data sheet. The first sheet contains the data 3 
sets of all studies under detailed analysis with the information obtained 4 
directly from each study and the second sheet contains each study results 5 
after the data uniformization procedure.  6 
 7 
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